Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
$5.88
+1.4%
$7.17
$3.80
$12.31
$769.22M1.37734,106 shs206,442 shs
Cue Health Inc. stock logo
HLTH
Cue Health
$0.15
+4.8%
$0.21
$0.13
$1.07
$23.41M1.23907,908 shs218,393 shs
Olink Holding AB (publ) stock logo
OLK
Olink Holding AB (publ)
$22.21
+0.8%
$23.33
$14.10
$26.01
$2.76B0.5683,242 shs238,545 shs
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
$1.46
-6.4%
$4.05
$1.25
$14.55
$391.21M1.839.80 million shs7.98 million shs
Quanterix Co. stock logo
QTRX
Quanterix
$16.25
-0.3%
$23.49
$11.39
$29.70
$621.56M1.3345,353 shs245,761 shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
-2.03%-3.65%-10.36%-33.79%-42.57%
Cue Health Inc. stock logo
HLTH
Cue Health
-2.83%-6.37%-24.48%-36.20%-86.57%
Olink Holding AB (publ) stock logo
OLK
Olink Holding AB (publ)
+0.73%-3.12%-9.38%-12.13%+0.55%
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
+0.65%-44.97%-57.61%-77.81%-85.83%
Quanterix Co. stock logo
QTRX
Quanterix
+2.97%-4.96%-30.13%-30.96%+26.16%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
1.2118 of 5 stars
3.30.00.00.01.13.30.6
Cue Health Inc. stock logo
HLTH
Cue Health
2.3001 of 5 stars
3.05.00.00.00.61.71.3
Olink Holding AB (publ) stock logo
OLK
Olink Holding AB (publ)
0.5817 of 5 stars
2.05.00.00.00.60.00.6
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
2.745 of 5 stars
4.31.00.00.02.01.71.3
Quanterix Co. stock logo
QTRX
Quanterix
3.1354 of 5 stars
3.65.00.00.03.12.50.0

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
2.60
Moderate Buy$9.0053.06% Upside
Cue Health Inc. stock logo
HLTH
Cue Health
2.00
Hold$3.001,931.14% Upside
Olink Holding AB (publ) stock logo
OLK
Olink Holding AB (publ)
2.00
Hold$26.0017.06% Upside
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
2.53
Moderate Buy$7.77432.38% Upside
Quanterix Co. stock logo
QTRX
Quanterix
3.17
Buy$32.0096.92% Upside

Current Analyst Ratings

Latest PACB, CTKB, OLK, HLTH, and QTRX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/22/2024
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOverweight ➝ Neutral
4/18/2024
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$9.00 ➝ $2.50
4/18/2024
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral$7.00 ➝ $2.50
4/18/2024
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Outperform ➝ Sector Outperform$15.00 ➝ $8.00
4/17/2024
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$12.00 ➝ $2.50
4/10/2024
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$8.00 ➝ $3.00
4/10/2024
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$9.00 ➝ $7.00
3/26/2024
Olink Holding AB (publ) stock logo
OLK
Olink Holding AB (publ)
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingEqual Weight ➝ Equal Weight$26.00
3/26/2024
Olink Holding AB (publ) stock logo
OLK
Olink Holding AB (publ)
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold$26.00
3/14/2024
Cue Health Inc. stock logo
HLTH
Cue Health
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral
3/6/2024
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$11.00 ➝ $10.00
(Data available from 4/23/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
$193.01M3.99$0.03 per share234.70$2.90 per share2.03
Cue Health Inc. stock logo
HLTH
Cue Health
$64.22M0.36N/AN/A$1.62 per share0.09
Olink Holding AB (publ) stock logo
OLK
Olink Holding AB (publ)
$169.60M16.28N/AN/A$4.04 per share5.50
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
$200.52M1.95N/AN/A$2.62 per share0.56
Quanterix Co. stock logo
QTRX
Quanterix
$122.37M5.08N/AN/A$9.17 per share1.77

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
-$12.15M-$0.09N/A84.00N/A-6.29%-1.40%-1.13%5/14/2024 (Estimated)
Cue Health Inc. stock logo
HLTH
Cue Health
-$373.46M-$2.44N/AN/AN/A-526.48%-67.82%-53.79%5/8/2024 (Estimated)
Olink Holding AB (publ) stock logo
OLK
Olink Holding AB (publ)
-$31.60M-$0.25N/A555.25N/A-18.63%-6.50%-5.63%5/9/2024 (Estimated)
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
-$306.73M-$1.21N/AN/AN/A-152.97%-40.23%-15.24%5/9/2024 (Confirmed)
Quanterix Co. stock logo
QTRX
Quanterix
-$32.33M-$0.86N/AN/AN/A-26.42%-9.15%-7.56%5/14/2024 (Estimated)

Latest PACB, CTKB, OLK, HLTH, and QTRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/9/2024N/A
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
-$0.26N/A+$0.26N/AN/AN/A  
3/25/2024Q4 2023
Olink Holding AB (publ) stock logo
OLK
Olink Holding AB (publ)
$0.14-$0.06-$0.20-$0.06$82.80 million$68.55 million
3/13/2024Q4 2023
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
N/A$0.04+$0.04$0.04$56.66 million$58.23 million
3/13/2024Q4 2023
Cue Health Inc. stock logo
HLTH
Cue Health
-$0.45-$0.32+$0.13$0.32$17.60 million$18.80 million
2/29/2024Q4 2023
Quanterix Co. stock logo
QTRX
Quanterix
-$0.28-$0.33-$0.05-$0.33$27.92 million$31.55 million    
2/15/202412/31/2023
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
-$0.29-$0.27+$0.02-$0.23$57.96 million$58.36 million    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
N/AN/AN/AN/AN/A
Cue Health Inc. stock logo
HLTH
Cue Health
N/AN/AN/AN/AN/A
Olink Holding AB (publ) stock logo
OLK
Olink Holding AB (publ)
N/AN/AN/AN/AN/A
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
N/AN/AN/AN/AN/A
Quanterix Co. stock logo
QTRX
Quanterix
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
N/A
6.97
5.89
Cue Health Inc. stock logo
HLTH
Cue Health
N/A
2.54
2.22
Olink Holding AB (publ) stock logo
OLK
Olink Holding AB (publ)
N/A
4.75
3.55
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
1.27
7.81
7.21
Quanterix Co. stock logo
QTRX
Quanterix
N/A
9.84
9.26

Ownership

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Cytek Biosciences, Inc. stock logo
CTKB
Cytek Biosciences
676130.82 million110.02 millionOptionable
Cue Health Inc. stock logo
HLTH
Cue Health
726158.52 million138.70 millionOptionable
Olink Holding AB (publ) stock logo
OLK
Olink Holding AB (publ)
707124.34 millionN/AOptionable
Pacific Biosciences of California, Inc. stock logo
PACB
Pacific Biosciences of California
796267.95 million264.20 millionOptionable
Quanterix Co. stock logo
QTRX
Quanterix
44138.25 million35.11 millionOptionable

PACB, CTKB, OLK, HLTH, and QTRX Headlines

SourceHeadline
Quanterix Co. (NASDAQ:QTRX) Receives Average Recommendation of "Buy" from BrokeragesQuanterix Co. (NASDAQ:QTRX) Receives Average Recommendation of "Buy" from Brokerages
americanbankingnews.com - April 16 at 4:22 AM
Quanterix (NASDAQ:QTRX)  Shares Down 7.5% Quanterix (NASDAQ:QTRX) Shares Down 7.5%
americanbankingnews.com - April 14 at 6:08 AM
Quanterix Co. (NASDAQ:QTRX) Short Interest Down 18.7% in MarchQuanterix Co. (NASDAQ:QTRX) Short Interest Down 18.7% in March
marketbeat.com - April 13 at 10:37 AM
Quanterix Asserts Tau Patent Claims as AD Testing Market Heats Up, but IP Defensibility a QuestionQuanterix Asserts Tau Patent Claims as AD Testing Market Heats Up, but IP Defensibility a Question
360dx.com - April 10 at 5:22 PM
Kent Lake Capital LLC Cuts Position in Quanterix Co. (NASDAQ:QTRX)Kent Lake Capital LLC Cuts Position in Quanterix Co. (NASDAQ:QTRX)
marketbeat.com - April 6 at 7:36 PM
Quanterix Co. (NASDAQ:QTRX) Director Laurie J. Olson Sells 1,000 SharesQuanterix Co. (NASDAQ:QTRX) Director Laurie J. Olson Sells 1,000 Shares
insidertrades.com - April 3 at 5:00 AM
Laurie J. Olson Sells 1,000 Shares of Quanterix Co. (NASDAQ:QTRX) StockLaurie J. Olson Sells 1,000 Shares of Quanterix Co. (NASDAQ:QTRX) Stock
marketbeat.com - April 2 at 6:51 PM
Quanterix (NASDAQ:QTRX)  Shares Down 7.7% Quanterix (NASDAQ:QTRX) Shares Down 7.7%
marketbeat.com - April 2 at 5:45 PM
Investing in Quanterix (NASDAQ:QTRX) a year ago would have delivered you a 111% gainInvesting in Quanterix (NASDAQ:QTRX) a year ago would have delivered you a 111% gain
finance.yahoo.com - April 1 at 11:13 AM
Quanterix’s Strong IP Position Fuels Buy Rating in Alzheimer’s Diagnostic MarketQuanterix’s Strong IP Position Fuels Buy Rating in Alzheimer’s Diagnostic Market
markets.businessinsider.com - March 27 at 9:23 AM
Analysts Are Bullish on Top Healthcare Stocks: Quanterix (QTRX), Passage Bio (PASG)Analysts Are Bullish on Top Healthcare Stocks: Quanterix (QTRX), Passage Bio (PASG)
markets.businessinsider.com - March 26 at 1:45 PM
Quanterix (NASDAQ:QTRX)  Shares Down 3.6% Quanterix (NASDAQ:QTRX) Shares Down 3.6%
marketbeat.com - March 26 at 12:39 PM
Analysts Are Bullish on Top Healthcare Stocks: Annovis Bio (ANVS), AbSci (ABSI)Analysts Are Bullish on Top Healthcare Stocks: Annovis Bio (ANVS), AbSci (ABSI)
markets.businessinsider.com - March 22 at 1:33 AM
Quanterix Outlines Partner Path With Labs to Expedite Building Global Alzheimer’s Disease Testing InfrastructureQuanterix Outlines Partner Path With Labs to Expedite Building Global Alzheimer’s Disease Testing Infrastructure
finance.yahoo.com - March 21 at 8:32 PM
Quanterix Outlines Partner Path With Labs to Expedite Building Global Alzheimers Disease Testing InfrastructureQuanterix Outlines Partner Path With Labs to Expedite Building Global Alzheimer's Disease Testing Infrastructure
businesswire.com - March 21 at 5:30 PM
QTRX Apr 2024 22.500 callQTRX Apr 2024 22.500 call
finance.yahoo.com - March 16 at 8:29 AM
QTRX Apr 2024 27.500 putQTRX Apr 2024 27.500 put
finance.yahoo.com - March 16 at 8:29 AM
CryoPort Q4 2023 Earnings PreviewCryoPort Q4 2023 Earnings Preview
msn.com - March 11 at 6:58 PM
Quanterix’s Growth Catalysts: FDA Breakthrough Designation and Alzheimer’s Diagnostic PotentialQuanterix’s Growth Catalysts: FDA Breakthrough Designation and Alzheimer’s Diagnostic Potential
markets.businessinsider.com - March 7 at 2:35 PM
Quanterix Granted Breakthrough Device Designation from U.S. FDA for Blood-Based p-Tau 217 Test for Alzheimers DiseaseQuanterix Granted Breakthrough Device Designation from U.S. FDA for Blood-Based p-Tau 217 Test for Alzheimer's Disease
stockhouse.com - March 6 at 7:24 PM
Quanterix (QTRX) AD Offering Gets FDAs Breakthrough Device TagQuanterix (QTRX) AD Offering Gets FDA's Breakthrough Device Tag
zacks.com - March 6 at 10:51 AM
Quanterix price target raised by $2 at Scotiabank, heres whyQuanterix price target raised by $2 at Scotiabank, here's why
realmoney.thestreet.com - March 4 at 2:16 PM
Quanterix Granted Breakthrough Device Designation from U.S. FDA for Blood-Based p-Tau 217 Test for Alzheimer’s DiseaseQuanterix Granted Breakthrough Device Designation from U.S. FDA for Blood-Based p-Tau 217 Test for Alzheimer’s Disease
finance.yahoo.com - March 4 at 9:15 AM
Quanterix Corporation (NASDAQ:QTRX) Just Released Its Annual Results And Analysts Are Updating Their EstimatesQuanterix Corporation (NASDAQ:QTRX) Just Released Its Annual Results And Analysts Are Updating Their Estimates
finance.yahoo.com - March 3 at 2:00 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Cytek Biosciences logo

Cytek Biosciences

NASDAQ:CTKB
Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, an automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in European, Latin American, and the Middle Eastern countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.
Cue Health logo

Cue Health

NASDAQ:HLTH
Cue Health Inc. operates as a healthcare technology company. It provides the Cue Health platform that offers individuals and healthcare providers convenient and personalized access to lab-quality diagnostic tests at home and at the point-of-care, as well as on-demand telehealth consultations and treatment options for a range of health and wellness needs. It offers Cue Integrated Care platform comprising hardware, software, and diagnostic components, such as Cue Health Monitoring System consisting of Cue Reader, a portable and reusable reader, Cue Cartridge, a single-use test cartridge, and Cue Wand, a sample collection wand; Cue Data and Innovation Layer, a solution with cloud-based data and analytics capability; Cue Virtual Care Delivery Apps, which include Cue Health App and Cue Enterprise Dashboard; and Cue Ecosystem Integrations and Apps, including integration with electronic medical record system, pharmacies and last-mile delivery, clinician networks, and laboratories. The company also provides COVID-19 testing kits. The company was formerly known as Cue Inc and changed its name to Cue Health Inc. in December 2017. Cue Health Inc. was incorporated in 2010 and is headquartered in San Diego, California.
Olink Holding AB (publ) logo

Olink Holding AB (publ)

NASDAQ:OLK
Olink Holding AB (publ) develops, produces, markets, and sells biotechnological products and services for the academic, government, biopharmaceutical, biotechnology, service provider, and other institutions that focuses on life science research. The company's products include Olink Explore that consist of Explore 372 and Explore 384 for cardiovascular and metabolic, oncology, neurology, and inflammation diseases; Olink Target product line; Olink Flex, a low-plex applications and use-cases; and Olink Focus product line that consists of custom developed solutions for customers that has identified various proteins of interest or a protein signature to focus on. Its products also comprise Olink Signature Q100, a qPCR readout platform; Olink Analysis services comprising study design and consultation, sample preparation and assay execution, and data processing and QC; and data analysis and bioinformatics services. In addition, the company offers Olink normalized protein expression (NPX) data processing software, a purpose-built software that enable users to import data, perform data analysis including visualizations, and statistical modelling; and Olink Insight, a cloud platform for Olink community to accelerate proteomics. It sells its products and services through its own direct sales force in Sweden, the United States, rest of the Americas, rest of Europe, the Middle East, Africa, Japan, and internationally. The company was formerly known as Knilo HoldCo AB and changed its name to Olink Holding AB (publ) in January 2021. Olink Holding AB (publ) was founded in 2004 and is headquartered in Uppsala, Sweden.
Pacific Biosciences of California logo

Pacific Biosciences of California

NASDAQ:PACB
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
Quanterix logo

Quanterix

NASDAQ:QTRX
Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications. It also provides SP-X instrument that is based on Simoa planar array technology for the measurement of multiplex chemiluminescent immunoassays. The company's products include assays include all components required to run enzyme-based immunoassay, such as beads, capture and detector reagents, and enzyme reagents and substrate; and replacement parts, reagents, and antibodies. In addition, it offers contract research services, including sample testing, homebrew assay development, custom assay development, lucent diagnostic, and LDT testing services. The company primarily operates in the areas of neurology, oncology, cardiology, infectious diseases, and inflammation. It sells its products for the life science research sector primarily to laboratories associated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research companies through a direct field sale, support organizations, and distributors or sales agents. The company was formerly known as Digital Genomics, Inc. and changed its name to Quanterix Corporation in August 2007. Quanterix Corporation was incorporated in 2007 and is headquartered in Billerica, Massachusetts.